Source: Annual Congress 2011 - The burden of pulmonary hypertension in respiratory disease
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Dorfmuller (Le Plessis-Robinson, France). Pulmonary vascular remodelling in pulmonary disease. Annual Congress 2011 - The burden of pulmonary hypertension in respiratory disease

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary vascular disease Source: HERMES Summer School 2014 - Educational material Year: 2014 Molecular determinants of cardiac and pulmonary vascular remodeling in scleroderma-related pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension in connective tissue diseases Year: 2008 Pulmonary vascular distensibility in pulmonary hypertension due to left heart disease Source: International Congress 2018 – Pulmonary hypertension: right ventricle function, haemodynamics and exercise Year: 2018 COVID-19 and the pulmonary circulation Source: ERS webinar 2020: COVID-19 and the pulmonary circulation Year: 2020 Pulmonary vascular reactivity in pulmonary hypertension due to left heart disease Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 mir-126 contribute to angiogenesis defect in pulmonary arterial hypertension right ventricle failure Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Smooth muscle microparticles as novel biomarkers of vascular remodelling and inflammation in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Pulmonary vascular diseases Source: ERS Course 2015 Year: 2015 Pulmonary vascular diseases Source: ERS Skills Course 2016 Year: 2016 Pulmonary vascular and cardiac impairment in interstitial lung disease Source: Eur Respir Rev 2017; 26: 160128 Year: 2017 The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations Source: Eur Respir Rev 2014; 23: 350-355 Year: 2014 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Relation between pulmonary arterial remodeling and parenchymal disease in severe COPD and interstitial lung disease patients Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Updates in pulmonary hypertension and other pulmonary vascular diseases Source: Breathe, 15 (3) 241; 10.1183/20734735.0187-2019 Year: 2019 Pulmonary hypertension and pulmonary vascular disease: course report Source: Breathe, 14 (1) e4; 10.1183/20734735.019917 Year: 2018 CPET in pulmonary vascular disease Source: ERS Skills course - Clinical exercise testing: advanced Year: 2018 Non-invasive haemodynamic measurement to detect treatment response in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary vascular injury, repair and remodelling in COPD patients Source: Annual Congress 2010 - Pulmonary vascular involvement in COPD Year: 2010 Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014